Impedimed LimitedASX: IPD

Quarterly Activities Report and Appendix 4C - Sep-2026 Qtr

· Issued by ImpediMed Limited via ASX

Filed with ASX · · 11 pages · English

Summary by 6ix AI

The report highlights a revenue increase compared to the previous quarter, alongside a notable annual recurring revenue figure. The company is focusing on expanding its market presence in cancer survivorship and has made significant changes to its sales leadership team to enhance performance. Additionally, the report outlines cash flow details, including net operating cash outflows and the company's current cash balance.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/quarterly-activities-report-and-appendix-4c-sep-2026-qtr-1

Watch Impedimed explain itImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29, 2026 · From 0:00 · Q1 Overview and Business Highlights

Release

ImpediMed Limited Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: [email protected] W : impedimed.com 30 October 2026 Companies Announcements Office Australian Securities Exchange Quarterly Activity and Cash Flow Report Key highlights for Q1 FY27 • Revenue of $3.8 million,...

Impedimed Limited on 6ix

In the deck

Story so far

Earlier from Impedimed

Later from Impedimed

All Impedimed news releases